VoxNeuro Awarded Patent, Appoints New CEO

It’s been a year of milestones so far for VoxNeuro Inc. 

Besides obtaining a patent (11278230, titled “Systems and methods for cognitive health assessment”) that protects its proprietary technology, VoxNeuro has appointed Jason Flowerday as CEO. Flowerday assumes leadership of the firm as it establishes a U.S.-based expert clinical study program to help expand VoxNeuro’s product offerings in various neurological pathologies. Since its inception, VoxNeuro has been led by co-founder James Connolly, son of John F. Connolly, Ph.D., the world-renowned neuroscientist responsible for the company’s cognitive assessment technology. With Flowerday as CEO, James Connolly will assume the new role of chief business officer, overseeing the organization’s key initiatives in the U.S. market.

“Jason’s entrepreneurial drive and commitment to being a champion for change, and the incredible amount of commercial success that he brings with him to VoxNeuro as its new chief executive officer, is a critical step forward on our mission to become The Brain Company.” said Connolly.

Flowerday brings more than 25 years of industry-relevant, executive leadership experience to VoxNeuro. His success in the life sciences and health technology sectors began with Bayer and Johnson & Johnson, followed by CEO roles across specialty pharmaceutical, medical device, diagnostics, and health tech companies. During his time leading these companies, Flowerday was successful in the pursuit of new markets, investment capital, revenue growth and multiple liquidity events. From 2018 to 2021, Flowerday was CEO for MDBriefCase, a global health tech company providing digital medical education to physicians, pharmacists and nurses. Through his stewardship, MDBriefCase was acquired by Think Research, a developer of knowledge-based digital healthcare solutions.
 
“I am excited to join VoxNeuro at this critical time in the organization’s growth. The team that James Connolly has assembled and the suite of SaMD products that are being built have all of the makings to change how brain health is understood on a global scale, resulting in the marked improvement of human lives. The company’s progress with its current product for general cognitive health assessment, plus significant advances with its intellectual property and its U.S. clinical program strategy, were the catalysts that convinced me that it was on a path to success in a nascent market ready for disruption.” said Flowerday.

Flowerday joins VoxNeuro as it prepares to solidify its product development plans and pipeline. After launching its first product last spring, a Software as a Medical Device (SaMD) general cognitive assessment that healthcare providers leverage in clinical decision-making, VoxNeuro is formalizing partnerships with channel partners to assist with its roll-out across the United States. In parallel, the company is working to finalize its initial clinical programs with leading American institutions and medical specialists to develop a series of diagnostic products for depression, concussion, Alzheimer’s, schizophrenia and bi-polar disorder. The company expects that these clinical programs will begin in the second half of 2022.
 
VoxNeuro is an SaMD brain health company that developed technology for analyzing brain-based biomarkers to assess cognitive function. It delivers a comprehensive understanding of how a brain is functioning by measuring attention and concentration, information processing, and working memory. The company’s technology is based on thorough research, with more than 300 peer-reviewed publications on EEG, including numerous breakthrough findings, published by Chief Science Officer John F. Connolly since 1982. The company’s competitive advantage involves EEG-based neuropsychological assessments that generate event-related potentials associated with key cognitive functions, and the output of a cognitive health report. VoxNeuro is headquartered at McMaster Innovation Park in Hamilton, Ontario, Canada.